According to the research report titled ‘North America Cardiac Ablation Market Forecast 2028 By End-use, By Product Ablators, By Approach, By Application, Research Report, Country Outlook, COVID-19 Impact Statistics, Country Outlook, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share’, available with MarketStudyReport, North America cardiac ablation market is anticipated to exceed USD 3.5 billion valuation by the year 2028.

Rising prevalence of heart diseases & strokes caused by unhealthy diets, insufficient physical exercise, smoking, and excessive alcohol consumption, ever-increasing geriatric population, and growing number of patients with abnormal heart rhythms are propelling North America cardiac ablation market growth.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4966038/

However, high risk associated with cardiac ablation operations and a stringent regulatory scenario may hamper the market outlook during the analysis timeframe.

In terms of approach, the market is bifurcated into open/surgical, and catheter based. Among these, the catheter-based segment accounted for 74% revenue share in 2021, owing to a number of advantages, including a reduced rate of recurrence, a shorter procedure time, and a decreased risk of side effects, as well as growing patient pool for atrial fibrillation and cardiac arrhythmia.

In terms of end-use terrain, North America cardiac ablation industry is divided into cardiac centers, ambulatory surgical centers, hospitals, and others. Out of which, cardiac centers segment generated revenues worth USD 290 million in 2021, due to the accessibility and availability of qualified healthcare personnel and cutting-edge medical technology in these settings.

Regionally, the U.S. market was valued at USD 1.2 billion in 2021 and is anticipated to progress with a CAGR of 14.2% during through 2028, because of increase in the prevalence of cardiovascular diseases, which is being attributed to changes in lifestyle patterns such as excessive alcohol consumption, smoking, and poor nutritional diets in the country.

Stereotaxis, Inc., MicroPort Scientific Corporation, Medtronic plc, Boston Scientific Corporation, Biotronik SE & Co. KG, Biosense Webster, Inc., AtriCure, Inc., AngioDynamics, Inc., and Abbott laboratories (St. Jude Medical) are the leading players in North America cardiac ablation market.